Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Gains from Sales and Divestitures (2022 - 2024)

Bolt Biotherapeutics' Gains from Sales and Divestitures history spans 3 years, with the latest figure at $41713.0 for Q4 2024.

  • For Q4 2024, Gains from Sales and Divestitures fell 28.12% year-over-year to $41713.0; the TTM value through Dec 2024 reached $41713.0, down 28.12%, while the annual FY2024 figure was $41713.0, 28.12% down from the prior year.
  • Gains from Sales and Divestitures for Q4 2024 was $41713.0 at Bolt Biotherapeutics, down from $58034.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $80533.0 in Q4 2022 and bottomed at $41713.0 in Q4 2024.
  • The 3-year median for Gains from Sales and Divestitures is $58034.0 (2023), against an average of $60093.3.
  • The largest annual shift saw Gains from Sales and Divestitures dropped 27.94% in 2023 before it decreased 28.12% in 2024.
  • A 3-year view of Gains from Sales and Divestitures shows it stood at $80533.0 in 2022, then decreased by 27.94% to $58034.0 in 2023, then decreased by 28.12% to $41713.0 in 2024.
  • Per Business Quant, the three most recent readings for BOLT's Gains from Sales and Divestitures are $41713.0 (Q4 2024), $58034.0 (Q4 2023), and $80533.0 (Q4 2022).